Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: Phase II clinical trial

被引：0
|
作者：
Fujimura, T. [1 ]
Yoshino, K. [2 ]
Kato, H. [3 ]
Fukushima, S. [4 ]
Otsuka, A. [5 ]
Matsushita, S. [6 ]
Fujisawa, Y. [7 ]
Ishizuki, S. [8 ]
Kambayashi, Y. [1 ]
Asano, Y. [1 ]
机构：
[1] Tohoku Daigaku, Dermatol, Sendai, Miyagi, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dermato Oncol, Tokyo, Japan
[3] Nagoya Shiritsu Daigaku, Dermatol, Nagoya, Aichi, Japan
[4] Kumamoto Daigaku, Dept Dermatol, Kumamoto, Kumamoto, Japan
[5] Kinki Daigaku, Dept Dermatol, Higashiosaka, Osaka, Japan
[6] Kokuritsu Byoin Kiko Kagoshima Iryo Ctr, Dermato Oncol, Kagoshima, Kagoshima, Japan
[7] Ehime Daigaku, Dermatol, Matsuyama, Ehime, Japan
[8] Tsukuba Daigaku, Dermatol, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1194
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [1] Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma
    Gibney, Geoffrey Thomas
    Pecora, Andrew L.
    Rapisuwon, Suthee
    Chen, Kevin
    Gardner, Kellie
    Cramer, Gayle
    Blair, Danielle
    Avergas, Amy
    Swanson, Nicole
    Ahn, Jaeil
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [3] Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma
    Nomura, M.
    Andoh, M.
    Yokota, T.
    Miyazaki, T.
    Satake, H.
    Iwasawa, S.
    Sonoda, A.
    Kato, K.
    Muto, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
    Joshi, Urvashi Mitbander
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason J.
    Zarour, Hassane M.
    Kirkwood, John M.
    Delgoffe, Greg M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A PHASE II TRIAL OF NIVOLUMAB PLUS AXITINIB IN PATIENTS WITH ANTI-PD1 REFRACTORY ADVANCED MELANOMA
    Shaikh, Saba
    Zang, Yan
    Wang, Hong
    Yang, Xi
    Sander, Cindy
    Rose, Amy
    Davar, Diwakar
    Luke, Jason
    Zarour, Hassane
    Kirkwood, John
    Delgoffe, Greg
    Najjar, Yana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A265 - A265
  • [6] Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma
    Juloori, Aditya
    Katipally, Rohan R.
    Lemons, Jeffrey M.
    Singh, Anurag K.
    Iyer, Renuka
    Robbins, Jared R.
    George, Ben
    Hall, William A.
    Pitroda, Sean P.
    Arif, Fauzia
    Fung, John
    Pillai, Anjana
    Liao, Chih-Yi
    Sharma, Manish
    Liauw, Stanley L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (01): : 202 - 213
  • [7] Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
    Nomura, Motoo
    Oze, Isao
    Masuishi, Toshiki
    Yokota, Tomoya
    Satake, Hironaga
    Iwasawa, Shunichiro
    Kato, Ken
    Andoh, Masashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 972 - 977
  • [8] Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
    Motoo Nomura
    Isao Oze
    Toshiki Masuishi
    Tomoya Yokota
    Hironaga Satake
    Shunichiro Iwasawa
    Ken Kato
    Masashi Andoh
    International Journal of Clinical Oncology, 2020, 25 : 972 - 977
  • [9] Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma
    Fecher, L. A.
    Nathanson, K.
    Flaherty, K. T.
    Amaravadi, R.
    Giles, L.
    McGettigan, S.
    Carberry, M.
    Elder, D.
    Schuchter, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A Phase 1 Clinical Trial of Ipilimumab, Nivolumab and Radiation Therapy for Patients with Metastatic Melanoma
    Barker, C. A.
    Postow, M. A.
    Goldman, D. A.
    Panageas, K. S.
    Halpenny, D.
    McCabe, D.
    Macri, M.
    Schwarzenberger, P.
    Ricciardi, T.
    Ryan, A.
    Venhaus, R.
    Knox, S. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S78 - S79
12345